Prescient Therapeutics

STEVEN YATOMI-CLARKE

CEO & MANAGING DIRECTOR

(ASX:PTX )

◾ Company Name: Prescient Therapeutics ◾ Company ASX code: PTX ◾ Key areas: Oncology, cell therapies (CAR-T cell therapy), targeted therapies ◾ Key Personnel: Steven Yatomi-Clarke, CEO & Managing Director | Dr Rebecca Lim, Senior VP of Scientific Affairs | Leanne West, Director of Clinical Operations ◾ Locations: Australia and United States ◾ Market Cap as of 15/09/22: $121.13M ◾ 52 Week share price as of 15 September: $0.115 - $0.305 ◾ Company Website: ptxtherapeutics.com

COMPANY PROFILE

When it comes to giving hope in finding a cure for cancer, global eyes are on Prescient Therapeutics (PTX) and its game-changing work in personalised cancer treatments.

Prescient is at the forefront of the personalised treatment revolution in oncology with a deep pipeline of innovative therapies.

Prescient has licensed technologies from and in collaboration with worldleading cancer centres in Australia and the US, such as Yale, Oxford, UPenn, MD Anderson and Peter Mac, with IP rights exclusively owned by Prescient.

Prescient is progressing clinical trials in two targeted therapies, PTX-100 and PTX-200, which are treating cancers of considerable unmet need.

PTX-100 is a first-in-class prenylation inhibitor that disrupts oncogenic Ras pathways in cancer cells, licensed from Yale. It is currently in a clinical trial in T cell lymphomas under the leadership of renowned haematologist, Professor Miles Prince, where it is demonstrating safety and exhibiting encouraging signs of efficacy in this difficult-to-treat patient population.

PTX-200 is a novel PH domain inhibitor that inhibits an important tumour survival pathway known as Akt, which plays a key role in development of many cancers, including breast and ovarian cancer, as well as leukaemia.

PTX-200 is currently in Phase 1b trial in relapsed and refractory Acute Myeloid Leukaemia – a disease with a grim prognosis. Four patients on the trial so far have had complete remissions with another patient experiencing a partial remission.

PTX-200 has also shown encouraging activity in a Phase 2a data in HER2negative breast cancer, and Phase 1b in recurrent or persistent platinum-resistant ovarian cancer.

When it comes to the ultimate goal of curing cancer, and not just delaying its progression, medical science has made a major leap forward in recent years with development of Chimeric Antigen Receptor (CAR) T cell therapies.

The new form of personalised immunotherapy uses a patient’s own T cells which are enhanced to enable them to seek and destroy cancer cells. Considered a game-changer, the treatment has shown exceptional promise as a cure with patients with certain blood cancers treated with CAR-T cell therapy remaining cancerfree for more than 10 years.

Prescient has two complementary, next generation cell therapy platforms capable of making next-generation CAR-T therapies safer, controllable, able to target any cancer and employ any immune cell. These platforms have yielded three in-house CAR-T therapies and presents a myriad of external partnering opportunities.

Prescient’s OmniCAR platform is a universal CAR-T platform which employs technology licensed from UPenn, the pioneer and world leader in CAR-T, as well as Oxford University.

OmniCAR-T cells go a step further than current CAR-T cell approaches with a modular universal immune receptor that can bind with any separate targeting ligand to potentially combat any form of cancer.

Prescient is developing next-generation CAR-T therapies on the OmniCAR platform for Acute Myeloid Leukaemia (AML), Her2+ solid tumours including breast, ovarian and gastric cancers, and glioblastoma multiforme (GBM). In addition, Prescient recently unveiled its complementary cell therapy enhancement platform CellPryme-M, which produces superior cells during the CAR-T cell manufacturing process.

Simply put, the cells are fitter and less prone to exhaustion, enabling longer duration of cancer killing activity. Prescient’s deep pipeline and scalable and diversified business model put it in a position to benefit from the current revolution in cancer cell therapy.

KEY INVESTMENT HIGHLIGHTS

AUGUST 16, 2022: Prescient enters a manufacturing services deal with Q-Gen Cell Therapeutics to produce its OmniCAR. cell lines for upcoming clinical trials. AUGUST 18, 2022: Prescient signs agreement to test automated, closed manufacturing solutions for OmniCAR platform. SEPTEMBER 7, 2022: Prescient announces strategic collaboration with MD Anderson Cancer Centre to develop unique blood cancer binders for OmniCAR.